2024
P3.13D.07 Longitudinal Tumor Microenvironment Analysis in Extensive Stage SCLC Patients Treated with Dual Checkpoint Inhibitor Blockade
Chiang A, Matera R, Ashley K, Rajendran B, Schalper K. P3.13D.07 Longitudinal Tumor Microenvironment Analysis in Extensive Stage SCLC Patients Treated with Dual Checkpoint Inhibitor Blockade. Journal Of Thoracic Oncology 2024, 19: s362. DOI: 10.1016/j.jtho.2024.09.652.Peer-Reviewed Original Research
2016
Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research
Schalper KA, Kaftan E, Herbst RS. Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research. Clinical Cancer Research 2016, 22: 2102-2104. PMID: 26957559, PMCID: PMC4940186, DOI: 10.1158/1078-0432.ccr-16-0169.Peer-Reviewed Original ResearchBasic Overview of Current Immunotherapy Approaches in Cancer
Velcheti V, Schalper K. Basic Overview of Current Immunotherapy Approaches in Cancer. American Society Of Clinical Oncology Educational Book 2016, 35: 298-308. PMID: 27249709, DOI: 10.1200/edbk_156572.Peer-Reviewed Original ResearchConceptsHost-tumor immune interactionsCurrent immunotherapy approachesPromising new therapeutic strategyRole of immunotherapyImmune checkpoint blockadeHost-tumor interactionsNew therapeutic strategiesCheckpoint blockadeImmunotherapy strategiesImmunotherapy approachesTreatment of cancerCombinatorial immunotherapyImmune interactionsTherapeutic strategiesImmune evasionImmunotherapyCancerMultiple mechanismsMalignancyBlockade